Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin

Neuroblastoma arises from the sympathetic nervous system and accounts for 15% of childhood cancer mortality. Amplification of the oncogene N-Myc is reported to occur in more than 20% of patients. While N-Myc amplification status strongly correlates with higher tumour aggression and resistance to treatment, the role of N-Myc in the aggressive progression of the disease is poorly understood. N-Myc being a transcription factor can modulate the secretion of key proteins that may play a pivotal role in tumorigenesis. Characterising the soluble secreted proteins or secretome will aid in understanding their role in the tumour microenvironment, such as promoting cancer cell invasion and resistance to treatment. The aim of this study is to characterise the secretome of human malignant neuroblastoma SK-N-BE2 (N-Myc amplified, more aggressive) and SH-SY5Y (N-Myc non-amplified, less aggressive) cells. Conditioned media from SK-N-BE2 and SH-SY5Y cell lines were subjected to proteomics analysis. We report a catalogue of 894 proteins identified in the secretome isolated from the two neuroblastoma cell lines, SK-N-BE2 and SH-SY5Y. Functional enrichment analysis using FunRich software identified enhanced secretion of proteins implicated in cysteine peptidase activity in the aggressive N-Myc amplified SK-N-BE2 secretome compared to the less tumorigenic SH-SY5Y cells. Protein-protein interaction-based network analysis highlighted the enrichment of cathepsin and epithelial-to-mesenchymal transition sub-networks. For the first time, inhibition of cathepsins by inhibitors sensitized the resistant SK-N-BE2 cells to doxorubicin as well as decreased its migratory potential. The dataset of secretome proteins of N-Myc amplified (more aggressive) and non-amplified (less aggressive) neuroblastoma cells represent the first inventory of neuroblastoma secretome. The study also highlights the prominent role of cathepsins in the N-Myc amplified neuroblastoma pathogenesis. As N-Myc amplification correlates with aggressive neuroblastoma and chemotherapy-based treatment failure, co-treatment with cathepsin inhibitors might be a better avenue for disease management.

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  L. Gangoda,et al.  Extracellular vesicles including exosomes are mediators of signal transduction: Are they protective or pathogenic? , 2015, Proteomics.

[3]  M. Fonović,et al.  Cysteine cathepsins and extracellular matrix degradation. , 2014, Biochimica et biophysica acta.

[4]  C. Thiele,et al.  Dihydropyrimidinase‐like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma , 2013, Cancer science.

[5]  Michael Liem,et al.  Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma , 2013, Proteomics.

[6]  M. Bogyo,et al.  Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. , 2013, Journal of the American Chemical Society.

[7]  J. Debski,et al.  Mass spectrometry identification of granins and other proteins secreted by neuroblastoma cells , 2013, Tumor Biology.

[8]  Vanessa Marchesi.  Breast cancer: Epithelial–mesenchymal transitions in human breast cancer samples , 2013, Nature Reviews Clinical Oncology.

[9]  S. Kaneko,et al.  Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma , 2012, International journal of oncology.

[10]  S. Mathivanan,et al.  Identifying mutated proteins secreted by colon cancer cell lines using mass spectrometry. , 2012, Journal of proteomics.

[11]  Gary D Bader,et al.  A travel guide to Cytoscape plugins , 2012, Nature Methods.

[12]  A. Gulino,et al.  Constitutive autotaxin transcription by Nmyc‐amplified and non‐amplified neuroblastoma cells is regulated by a novel AP‐1 and SP‐mediated mechanism and abrogated by curcumin , 2012, FEBS letters.

[13]  S. Mathivanan.  Quest for Cancer Biomarkers: Assaying Mutant Proteins and RNA that Provides the Much Needed Specificity , 2012 .

[14]  M. Yoshikawa,et al.  Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines , 2011, International journal of oncology.

[15]  Dimitris Anastassiou,et al.  Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo , 2011, BMC Cancer.

[16]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[17]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[18]  星野 宏光.  Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer , 2011 .

[19]  Maria P. Pavlou,et al.  The cancer cell secretome: a good source for discovering biomarkers? , 2010, Journal of proteomics.

[20]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[21]  Aimee L. Alphonso,et al.  Stromal cells and integrins: conforming to the needs of the tumor microenvironment. , 2009, Neoplasia.

[22]  Sung-Eun Jung,et al.  Neuroblastoma: treatment outcome after incomplete resection of primary tumors , 2009, Pediatric Surgery International.

[23]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[24]  D. Peeper,et al.  Senescence-messaging secretome: SMS-ing cellular stress , 2009, Nature Reviews Cancer.

[25]  Donald J. Johann,et al.  Cancer and the tumor microenvironment: a review of an essential relationship , 2009, Cancer Chemotherapy and Pharmacology.

[26]  I. Øra,et al.  mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high‐risk disease when measured at diagnosis , 2008, International journal of cancer.

[27]  J. Izbicki,et al.  Universal expression of cell adhesion molecule NCAM in neuroblastoma in contrast to L1: implications for different roles in tumor biology of neuroblastoma? , 2008, Pediatric Surgery International.

[28]  F. Westermann,et al.  Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. , 2008, Carcinogenesis.

[29]  E. Diamandis,et al.  Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.

[30]  Tatiana Tatusova,et al.  NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins , 2004, Nucleic Acids Res..

[31]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[32]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[33]  K. S. Deshpande,et al.  Human protein reference database—2006 update , 2005, Nucleic Acids Res..

[34]  M. Bogyo,et al.  An Improved Preparation of the Activity-Based Probe JPM-OEt and In Situ Applications , 2005 .

[35]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[36]  P. Tam,et al.  Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma , 2004, Oncogene.

[37]  P. Démoulin,et al.  Ju n 20 07 Progressive transformation of a flux rope to an ICME Comparative analysis using the direct and fitted expansion methods , 2008 .

[38]  C. Thiele,et al.  Modulation of N-myc expression alters the invasiveness of neuroblastoma , 1997, Clinical & Experimental Metastasis.

[39]  D. Radisky,et al.  Cancer. Respect thy neighbor! , 2004, Science.

[40]  Mina J Bissell,et al.  Tumor reversion: Correction of malignant behavior by microenvironmental cues , 2003, International journal of cancer.

[41]  J. Kos,et al.  Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. , 2003, Experimental cell research.

[42]  N. Pouliot,et al.  Laminin 10/11: an alternative adhesive ligand for epidermal keratinocytes with a functional role in promoting proliferation and migration , 2002, Experimental dermatology.

[43]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[44]  T. Tlsty,et al.  Stromal cells can contribute oncogenic signals. , 2001, Seminars in cancer biology.

[45]  M Schwab,et al.  N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.

[46]  P. Farnham,et al.  Direct recruitment of N‐myc to target gene promoters , 2000, Molecular carcinogenesis.

[47]  R. Perris,et al.  Role of the extracellular matrix during neural crest cell migration , 2000, Mechanisms of Development.

[48]  S. Reddy,et al.  Isolation and characterization of the human secretogranin II gene promoter. , 2000, Brain research. Molecular brain research.

[49]  S Grilli,et al.  Effects of the protease inhibitor antipain on cell malignant transformation. , 1999, Anticancer research.

[50]  E. Sher,et al.  Immunolocalization of secretogranin II, chromogranin A, and chromogranin B in differentiating human neuroblastoma cells. , 1992, European journal of cell biology.

[51]  S. Ferrari,et al.  Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.